降低TIPS后的白内素-6水平预测了去补偿性肝硬化结果
Andrea Kornfehl1,2, Anja Tiede3,4, Paul Hemetsberger1,2
1Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
JHEP reports : innovation in hepatology
|March 24, 2025
概括
跨内肝移植系统分流 (TIPS) 有效地降低了肝硬化患者的全身炎症 (SI). 在TIPS后3个月内,白血素-6 (IL-6) 水平的下降独立地降低了急性-慢性肝衰竭和肝脏相关死亡的风险.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
背景情况:
- 系统性炎症 (SI) 是不补偿性晚期慢性肝病 (dACLD) 疾病进展的关键驱动因素.
- 急性至慢性肝衰竭 (ACLF) 和与肝脏相关的死亡是与肝硬化中的SI相关的重大并发症.
- 跨内肝移植系统分流 (TIPS) 是治疗肝硬化并发症的有效方法.
研究的目的:
- 评估TIPS植入后系统性炎症参数的变化.
- 确定这些变化对患者结局的临床影响,包括ACLF和肝脏相关死亡.
主要方法:
- 一项前性研究包括109名接受选择性TIPS植入的患者.
- 干白素-6 (IL-6) 水平在基线和TIPS后3个月被测量. 在一个子组中,C-反应蛋白 (CRP) 和脂多糖结合蛋白 (LBP) 也被评估.
- 使用竞争性风险回归分析来评估IL-6降低与临床结果之间的关联.
主要成果:
- 在TIPS后3个月,大多数患者的IL-6水平显著下降 (63.8%在维也纳,68.6%在汉诺威).
- 对于CRP和LBP也观察到类似的减少.
- 3个月后IL-6的降低独立地与发展ACLF和肝脏相关死亡的风险降低有关.
结论:
- TIPS的植入导致了不补偿性肝硬化患者系统性炎症和细菌转移的持续减少.
- 在TIPS后3个月降低IL-6水平是对ACLF和肝脏相关死亡率的重要保护因素.
- TIPS在肝硬化患者的系统性炎症中显示出临床上有意义的减少.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
386
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
386
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
274
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
274
Cirrhosis I: Introduction
30
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
30
Cirrhosis II: Pathophysiology
49
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to...
49


